pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›ADBRY
drug
save

ADBRY

updated 3mo ago
by Leo Pharma AS
community read0 votes

🐶 often sniffed alongside

top 5
  • drugtralokinumab32 co-mentions · 8 sources
  • tagApproval28 co-mentions · 7 sources
  • companyLEO Pharma Inc20 co-mentions · 8 sources
  • companyLeo Pharma AS14 co-mentions · 7 sources
  • tagRecall2 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying ADBRY

  • phase2Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)completedn=28
  • phase1A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjectscompletedn=101
  • phase3A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitisrecruitingn=195
  • —Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impactrecruitingn=30
  • phase3A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapycompletedn=235
  • phase3Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)completedn=794
  • phase3Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)completedn=136
  • phase3Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3completedn=380
more trials →

News(3)

  • LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
    This is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year.
    biospace · 2d ago
  • Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod
    Leo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the…
    fiercebiotech · 3d ago
  • Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
    Infinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.
    biopharma_dive · 9d ago
brand
ADBRY
generic
TRALOKINUMAB
Data sources
ClinicalTrials.gov
last refreshed 2m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?